To find the major nodes, we selected 8 targets based on an average value of degree ≥ 1.52, namely, neuronal acetylcholine receptor subunit alpha-3 (CHRNA3), D(2) dopamine receptor (DRD2), protein kinase C alpha type (PRKCA), cyclin-dependent kinase 1 (CDK1), cyclin-dependent kinase 2 (CDK2), neuronal acetylcholine receptor subunit alpha-5 (CHRNA5), interstitial collagenase (MMP1), and matrix metalloproteinase-9 (MMP9), indicating that they were likely to be potential targets of CKI for the treatment of LC. This evidence concerns the gene PRKCA and laryngotracheoesophageal cleft.